#USA #Waters Corporation #Milford, Massachusetts #Halo Labs #Wyatt Technology

Waters Corporation and Halo Labs: A Strategic Acquisition

In an exciting development for the biopharmaceutical sector, Waters Corporation (NYSE: WAT) has announced its acquisition of Halo Labs™. This innovative company specializes in imaging technologies designed to detect, identify, and count interfering particles in therapeutic products like cellular, protein, and gene therapies.

The integration of Halo Labs’ cutting-edge Aura™ platform will significantly bolster Waters' capabilities in particle analysis, which is crucial for ensuring the safety and efficacy of therapeutic products. The Aura platform employs advanced technology to carry out full-spectrum particle analysis, providing invaluable insights that strengthen the quality control processes within biopharmaceutical production.

Enhancements to Particle Analysis Technology

Waters’ acquisition is particularly timely as the demand for therapies like CAR-T is surging. Halo Labs' sub-visible particle technology adds a new dimension to the analysis of external particles used in CAR-T cell amplification, which are often undetectable by conventional methods. This breakthrough allows for the early identification of translucent impurities, ultimately enhancing patient safety and therapeutic outcomes.

Dr. Udit Batra, President and CEO of Waters Corporation, emphasized the significance of this acquisition, stating, "The addition of Halo Labs' high-throughput, low-sample-volume technology enables a wide range of sample types and volumes to be analyzed. This will allow for earlier insights during therapy development and greater safety in manufacturing processes." Such advancements not only elevate Waters' analytical technologies but also reaffirm the company’s commitment to remain at the forefront of biopharmaceutical solutions.

Accelerating Growth and Innovation

Both Waters and Halo Labs share a vision of innovation and customer-centric solutions. Rick Gordon, CEO of Halo Labs, expressed enthusiasm about the merger, noting that the collaboration would expedite the development of their platform while maintaining high standards for quality and safety. This partnership is designed to enhance therapeutic development and production efforts, striving for breakthroughs that ultimately benefit patients worldwide.

The acquisition of Halo Labs is expected to have a minimal impact on Waters Corporation's earnings over the next 12 months. However, merging the resources and expertise of these two companies promises to accelerate the growth of Waters in analytical testing and bioprocessing for large-molecule therapies.

About Halo Labs

Halo Labs is a venture-backed scientific instrumentation and consumables company that provides high-throughput tools for assessing formulation, stability, and quality of biopharmaceutical products. Their state-of-the-art optics and image processing techniques have made them a key partner for biopharmaceutical companies globally, offering unprecedented insights into their products.

About Waters Corporation

With over 65 years of experience, Waters Corporation is a global leader in analytical instruments, separation technologies, and software, serving sectors like life sciences, materials science, food safety, and environmental analysis. The company’s commitment to helping its clients produce safe drugs, ensuring food safety, and maintaining water purity has positioned it as a trusted partner worldwide. With over 7,600 dedicated employees operating in more than 100 countries, Waters continues to drive innovation in laboratories, production sites, and hospitals, enhancing the benefits of scientific advances.

In summary, Waters Corporation’s acquisition of Halo Labs not only reflects a strategic move in expanding its technological portfolio but also highlights the increasing importance of thorough analytical practices in the biopharmaceutical industry. As the demand for innovative therapies grows, Waters is poised to lead the charge in delivering advanced solutions that promise better health outcomes for patients.